Total Funding
49
Total FundingPost-IPO Equity raised
Growth Score
pts
Heat Score
22 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
8271
CinCor is a clinical-stage biopharmaceutical company that develops treatments for cardiovascular diseases.
- Jon Isaacsohn: CEO & Co FounderPast Role: Teva Pharmaceuticals, Chief Executive Officer
- Mason W. Freeman: Executive VP Clinical Operations
About the Company
CinCor is a clinical-stage biopharmaceutical company with a mission to advance promising clinical candidates toward marketing approval. CinCor’s focus is on cardiovascular, metabolic and kidney diseases. CinCor has program is CIN-107, a novel aldosterone synthase inhibitor.
Women Founded
